Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Piper Sandler in a research report issued on Tuesday,Benzinga reports. They currently have ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Thank you for standing by. My name is Briana, and I will be your conference operator today. At this time, I’d like to welcome everyone to ...

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

We recently compiled a list of the 10 AI News You Shouldn’t Miss. In this article, we are going to take a look at where ...

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting CHICAGO, November 07, 2024--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the ...

Thank you, Briana. Good afternoon, and welcome to Tempus’ third quarter 2024 conference call. This afternoon, Tempus released results for the quarter ending September 30, 2024. Joining me today from ...

My name is Brianna, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Tempus AI Third Quarter 2024 Financial Results Conference Call. (Operator ...